

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 January 2025 (09.01.2025)



(10) International Publication Number
WO 2025/008323 A1

(51) International Patent Classification:

C12N 15/62 (2006.01) *C07K 16/18* (2006.01)
A61K 38/00 (2006.01) *C07K 16/32* (2006.01)
C07K 14/005 (2006.01) *C12N 7/00* (2006.01)
C07K 16/00 (2006.01) *C12N 15/10* (2006.01)
C07K 16/10 (2006.01) *C12N 15/86* (2006.01)

(21) International Application Number:

PCT/EP2024/068552

(22) International Filing Date:

02 July 2024 (02.07.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/511,793 03 July 2023 (03.07.2023) US

(71) Applicant: **UCB BIOPHARMA SRL** [BE/BE]; Allée de la Recherche, 60, 1070 Brussels (BE).

(72) Inventors: **KAS, Onur Yusuf**; c/o IPD, UCB Biopharma SRL, Allée de la Recherche, 60, 1070 Brussels (BE). **KRAMER, Tal**; c/o IPD, UCB Biopharma SRL, Allée de la Recherche, 60, 1070 Brussels (BE). **LAWSON, Alastair David Griffiths**; c/o IPD, UCB, 208 Bath Road, Slough Berkshire SL1 3WE (GB). **MACPHERSON, Alexander**; c/o IPD, UCB, 208 Bath Road, Slough Berkshire SL1 3WE (GB). **SCHULZE, Monika-Sarah Elisabeth Dorothea**; c/o IPD, UCB, 208 Bath Road, Slough Berkshire SL1 3WE (GB). **XU, Meiyu**; c/o IPD, UCB Biopharma SRL, Allée de la Recherche, 60, 1070 Brussels (BE).

(74) Agent: **UCB INTELLECTUAL PROPERTY**; UCB, 208 Bath Road, Slough Berkshire SL1 3WE (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: ENGINEERED AAV CAPSID PROTEINS

(57) Abstract: The present disclosure relates to an engineered capsid protein comprising an AAV capsid protein and an antibody fragment, wherein the antibody fragment comprises a bovine ultralong CDR-H3, or a portion thereof. The present disclosure also relates to an engineered capsid protein comprising an AAV capsid protein and an antibody fragment, wherein the antibody fragment comprises a knob domain of an ultralong CDR-H3, or a portion thereof. The disclosure further relates to a capsid comprising an engineered capsid protein, and to recombinant AAVs comprising said engineered capsid protein or capsid, and their use in therapy. The present disclosure also extends to methods of preparing said engineered capsid proteins, capsids and AAVs.



WO 2025/008323 A1